杨华夏;张奉春;
YANG Hua-xia;ZHANG Feng-chun;Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases,Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院风湿免疫科国家皮肤与免疫疾病临床医学研究中心风湿免疫病学教育部重点实验室

摘要(Abstract)：

随着贝利木单克隆抗体(肿瘤坏死因子家族B细胞活化因子拮抗剂)在中国用于治疗系统性红斑狼疮(systemic lupus erythematosus, SLE)适应证的获批,SLE的治疗逐渐迈向了生物制剂时代。SLE发病机制复杂,包括B细胞和T细胞免疫耐受机制的破坏。本文关注SLE的新型生物治疗靶点,以及正在进行的SLE临床试验,围绕靶向B细胞特异性表面分子(CD20、CD19),靶向B细胞信号通路和细胞因子(肿瘤坏死因子家族B细胞活化因子、增值诱导配体),靶向共刺激因子减少B细胞抗原呈递(CD40及其配体、可诱导共刺激分子及其配体),以及T细胞及信号通路(rigerimod、干扰素α、JAK-STAT)等SLE相关靶标展开讨论。总而言之,生物靶向治疗SLE已获得一定进展,未来前景可期。
Belimumab is a human monoclonal antibody that inhibits B-cell activating factor of the tumor necrosis factor family(BAFF). With the approval of belimumab for treating patients with systemic lupus erythematosus(SLE), targeted biologics has generally ushered a new era in the treatment of SLE. The pathogenesis of SLE involves a general breakdown in both B cell and T cell tolerance. In this review, we focused on the new promising therapeutic targets and several ongoing clinical trials for SLE. The approaches of these biologic therapeutic agents included targeting B cell selective cell surface molecules(CD20 or CD19), inhibiting B cell survival by targeting cytokines and signaling molecules(BAFF or a proliferation-inducing ligand), interfering with B cell antigen presentation by targeting co-stimulatory molecules(CD40-CD40 ligand interactions or ICOS-ICOS ligand interactions), blocking the signal pathways(rigerimod, interferon-α, or JAK/STAT), et al. Biologic target therapies for SLE have made some progress and bringing successful new biologic therapies into the clinical practice for SLE remains challenging but promising in the future.

关键词(KeyWords)： 系统性红斑狼疮;生物制剂;治疗靶点;临床试验
systemic lupus erythematosus;biologics;therapeutic target;clinical trial

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81801633)

作者(Authors): 杨华夏;张奉春;
YANG Hua-xia;ZHANG Feng-chun;Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases,Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College;

参考文献(References)：

• [1] Zhang F,Bae SC,Bass D,et al.A pivotal phase Ⅲ,randomised,placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China,Japan and South Korea[J].Ann Rheum Dis,2018 ,77:355- 363.
• [2] 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组.2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志,2020,59:172- 185.
• [3] Fanouriakis A,Kostopoulou M,Alunno A,et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis,2019,78:736- 745.
• [4] US National Library of Medicine.A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) [EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT02550652.
• [5] Aranow C,DallEra M,Byron M,et al.Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis[J].Arthritis Rheumatol,2018,70:1870.
• [6] ISRCTN Registry.Belimumab after B cell depletion therapy as a new treatment for patients with systemic lupus erythematosus (SLE)[EB/OL].http:// www.isrctn.com/ISRCTN47873003.
• [7] US National Library of Medicine.Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)[EB/OL].https://www.clinicaltrials.gov/ct2/show/ NCT04082416.
• [8] Merrill JT,June J,Koumpouras F,et al.Top-line results of a phase 2,double-blind,randomized,placebo-controlled study of a reversible B cell inhibitor,XmAb?5871,in systemic lupus erythematous (SLE)[J].Arthritis Rheumatol,2018,70:L19.
• [9] Hutcheson J,Vanarsa K,Bashmakov A,et al.Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus[J].Arthritis Res Ther,2012,14:R243.
• [10] US National Library of Medicine.Study of the Safety and Efficacy of GDC- 0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus[EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT02908100.
• [11] US National Library of Medicine.A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus [EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT02804763.
• [12] Sullivan BA,Tsuji W,Kivitz A,et al.Inducible T cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus[J].Lupus Sci Med,2016,3:e000146.
• [13] Sascha T,Claudia K,David P,et al.SM101,a novel recombinant,soluble,human FcγⅡB receptor,in the treatment of systemic lupus erythematosus:results of a double- blind,placebo-controlled multicenter study[J].Arthritis Rheum,2014,66:2833.
• [14] US National Library of Medicine.A 52-Week,Randomized,Double-Blind,Parallel-Group,Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP- 201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (LUPUZOR) [EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT02504645.
• [15] US National Library of Medicine.Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis (TULIP-LN1) [EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT02547922.
• [16] US National Library of Medicine.Safety of Tofacitinib,an Oral Janus Kinase Inhibitor,in Systemic Lupus Erythematosus [EB/OL].http://www.clinicaltrials.gov/ct2/show/ NCT02535689.
• [17] US National Library of Medicine.A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (BRAVE Ⅱ) [EB/OL].http://www.clinicaltrials.gov/ct2/show/ NCT03616964.
• [18] US National Library of Medicine.A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I) [EB/OL].http://www.clinical-trials.gov/ct2/show/NCT03616912.
• [19] van Vollenhoven RF,Hahn BH,Tsokos GC,et al.Efficacy and safety of ustekinumab an IL- 12 and IL- 23 inhibitor,in patients with active systemic lupus erythematosus:results of a multicenter,double-blind,phase 2,randomized,control-led study[J].Lancet ,2018,392:1330- 1339.
• [20] National Library of Medicine.A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus[EB/OL].http://www.clinicaltrials.gov/ct2/show/NCT03517722.